American Autonomic Society

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Retrieved on: 
Thursday, November 16, 2023
SEQUOIA, American Autonomic Society, Autonomic nervous system, OHQ, Orthostatic hypotension, AAS, Patient, University School, Research, Week, Noh, Neurology, Dysautonomia, Pharmaceutical industry, Medical imaging

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.
  • Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of changes in patient-reported outcomes measures such as the Orthostatic Hypotension Questionnaire (OHQ).
  • This anchor-based analysis model will aid in the interpretation of clinically meaningful changes to the OHSA composite score observed in CYPRESS.
  • Further, establishment of an anchor-based, clinically meaningful change in the OHSA composite primary endpoint will be important for clinicians, regulators, and payors.

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

Retrieved on: 
Monday, February 27, 2023
Janus, Orthostatic hypotension, Chronic obstructive pulmonary disease, Blood pressure, JAK, Telephone, Atrophy, Norepinephrine, SG, American Autonomic Society, GSK, Internet, MBA, Research, Noh, Owens & Minor, Executive, Maintenance, J.P. Morgan & Co., Partnership, Webcast, FDA, Patient, R, MSA, Janssen, Growth, Research and development, Wesleyan University, COPD, Bank statement, CIBC, CIBC World Markets, Columbia University, Hypertension, Asthma, Sale, BA, Merrill (company), Multiple system atrophy, Medication, Administration, Pharmaceutical industry, Cryptocurrency, Beauty salon, Holding company, Fine chemical, Management, Viatris

Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.

Key Points: 
  • Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.
  • In the fourth quarter of 2022, Theravance Biopharma recognized its first revenue associated with non-US YUPELRI royalties.
  • Cash burn in fourth quarter of 2022 was $7 million excluding a $118 million tax payment and $34 million of share repurchases.
  • A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 29, 2023.

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Associate, USP, Blood pressure, Central nervous system, Company, Annual conferences, Multiple system atrophy, SAN, Multimedia, Rigidity, Death, FDA, Population, Biomarker, Spinal cord, ASX, Conference, Royal commission, Urination, Brain, Vanderbilt University Medical Center, Biomusic, Poster, Quality of life, Movement, Therapy, Dysautonomia, Neurodegeneration, AAS, American Autonomic Society, European Commission, HIV disease progression rates, Board of High School and Intermediate Education Uttar Pradesh, CEO, MSA, View, Parkinson's disease, Pathology, ATH, Neurology, NASDAQ, Falls, Autonomic nervous system, Disease, Principal investigator, Overactive bladder, Patient, MD, Drug discovery, Pharmaceutical industry, Medical imaging, Parkinsonism, Alterity

Multiple System Atrophy (MSA) is a progressive neurodegenerative disease that presents with motor and prominent autonomic symptoms.

Key Points: 
  • Multiple System Atrophy (MSA) is a progressive neurodegenerative disease that presents with motor and prominent autonomic symptoms.
  • Problems with urination are a common symptom experienced in MSA and can occur at any time during the disease process.
  • The USP is a questionnaire that comprehensively assesses stress incontinence, overactive bladder, and urinary obstruction signs and their severity.
  • In addition to completing the USP questionnaire, all participants completed a neurologic examination and were assessed using rating scales for MSA.

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Retrieved on: 
Wednesday, November 2, 2022
American Autonomic Society, AAS, Center, Clinical trial, Parkinson's disease, Autonomic nervous system, Biopharma LLC, NASDAQ, Company, Pure autonomic failure, Autonomic, Patient, Multiple system atrophy, Noh, International Symposium on Endovascular Therapy, 2021 Essex County Council election, Drug development, Bachelor of Medicine, Bachelor of Surgery, LS, Quality of life, Beth Israel Deaconess Medical Center, Orthostatic hypotension, MSA, Caregiver burden, Pharmaceutical industry, Hydraulic machinery, Neurology

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).

Key Points: 
  • DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
  • Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
  • "These ampreloxetine data are encouraging for patients with MSA suffering with neurogenic orthostatic hypotension.
  • MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system.